Lausanne, landscape and its impact on the pharmaceutical industry
09:00 France
AMC Alliances
Anna Matranga, Strategic Sourcing R&D, Consultant, AMC Alliances & Consulting, France

The world in reset mode: The new world competitiveness landscape and its impact on the pharmaceutical industry
Stephane Garelli, Professor of competitiveness (nations and enterprises), IMD Business School in Lausanne and University of Lausanne, Switzerland

07:30 Registration and Morning Coffee
08:50 Opening remarks from the Chairperson
Anna Matranga, Strategic Sourcing R&D, Consultant, AMC Alliances & Consulting, France

09:00 The world in reset mode: The new world competitiveness
11:30 CASE STUDY: New data and insights characterizing the changing CRO landscape and its role in integrating clinical research with clinical care
Professor Ken Getz, Director, Tufts Center for the Study of Drug Development Tufts University (CSDD), USA

10:55 Opening remarks from the Chairperson
Dr Raphaele Mary, Director, Capability and Strategy, Central Clinical Planning & Solutions, Global Clinical Operations, Bristol-Myers Squibb, France

11:00 CASE STUDY: Long term collaborations within a study program
Peter Van Der Ark, Clinical Research Manager, Experimental Medicine Neuroscience, Janssen – Pharmaceutical Companies of J&J, Belgium

11:30 PRESENTATION: The Importance of patient retention - recruit to retain
Kate O’Brien, Senior Research Nurse, Albany House Medical Centre, UK
Amanda Perry, Research Practitioner, Albany House Medical Centre, UK

11:30 PANEL: A partnership/collaboration from Bayer through setting up and implementing a global FSP strategy on a local level
Keith Francis, Strategic Alliance Management, Global Clinical Development Operations, Bayer AG
Gill Roberts, Strategic Sourcing, Global BP & D Services, Medical Affairs & Commercialisation, Bayer AG

11:30 PRESENTATION: Using patients own devices to capture quality of life and other health data
Bruce Hellman, CEO, Co-Founder, uMotif, UK

11:30 Title TBC
Vanessa Reddy, Strategic Innovation Leader, Roche, Switzerland

11:30 INNOVATION DEN:
Moderator: Julianne Hull, Chief Executive Officer, WenStar, UK
Characterization of individual patient placebo response: Positive impact on clinical trial results
Dominique Demolle, Chief Executive Officer, Tools 4 Patient, Belgium

09:40 Panel: The partnership landscape - New partnerships, new innovations, new processes
MODERATOR: Phil Hammond GP and Broadcaster
Sheryl Jacobs, Vice President, Global Development Operations, Amgen Inc, USA
Barbara Voith, Vice President, Head Global CS Operations, Bayer HealthCare, Germany
Dr Emma Dean, Director Physician, Early Clinical Development, Oncology Translational Medicine Unit, AstraZeneca, UK
Hanne Lang, Vice President, Clinical Systems and Data Management, Novo Nordisk
Bryan Katz, Managing Director of Consulting, INC Research/ inVentiv Health, USA

12:00 INNOVATION DEN:
Moderator: Julianne Hull, Chief Executive Officer, WenStar, UK
Characterization of individual patient placebo response: Positive impact on clinical trial results
Dominique Demolle, Chief Executive Officer, Tools 4 Patient, Belgium

12:00 PRESENTATION: The EU Clinical Trials Regulation: Are you prepared for its implementation?
Dr Martine Dehlinger-Kremer, Vice President, Global Medical and Regulatory Affairs, SynteractHCR

10:20 Morning Coffee and Networking sponsored by M E D P A C E
|-------|----------------------------------------|---------------------------------------------------------------|--------------------------|----------------------------------------|
| 14:00 | DUAL DIALOGUE: Eli Lilly and Covance clinical pharmacology: A partnership that has existed for more than 10 years | KEYNOTE CASE STUDY: Informed consent and participant engagement in the age of digital platforms | KEYNOTE CASE STUDY: Experiences and lessons learned from conducting global mHealth enabled trials | CASE STUDY: Implementation of a global governance structure to manage and oversee SOPs/training distribution to global and local external partners
|       | Dr Tamzin Blagbrough, Sourcing Consultant, Clinical Pharmacology Study Delivery Solutions, Eli Lilly and Company Limited, UK | Dr James Teo, Neurologist and Clinical Trialist, Kings College Hospital NHS Foundation Trust, UK | Daisy Daeschler, Research Partnerships Officer, The Michael J Fox Foundation, USA | Oliver Fink, Head Global QM Systems & Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
|       | Dave Simpson, Executive Director, Clinical Pharmacology Services, Covance, UK | MODERATOR: Fraser Inglis, Consultant Physician & Director, Glasgow Memory Clinic, UK | Dr Marjan Faber, Senior Research Fellow in Patient Participation for Quality Improvement in Health Care, Radboud University Medical Center, The Netherlands |
| 14:30 | PANEL: Recruitment from the perspective of an investigative Site – pitfalls and strategies | PANEL: Recruitment from the perspective of an investigative Site – pitfalls and strategies | PRESENTATION: Putting IoT to work for caregivers in clinical trials with 3G-enabled medical devices. Moving away from Bluetooth connected devices to intelligent connected care. | PANEL: Focus on operational risk based approaches to oversight and quality management with the new ICH E6R2 guidelines - How to interpret this and how are companies dealing with it?
|       | Julianne Hull, Chief Executive Officer, WenStar, UK | MODERATOR: Fraser Inglis, Consultant Physician & Director, Glasgow Memory Clinic, UK | Dr Helena Sigal, Managing Director, Sigal Site Management and Support, Germany | MODERATOR: Patricia Leuchten, President & Chief Executive Officer, Avoca Group
|       | Nicole Jansen, Senior Outsourcing and Contract Manager, Grunenthal GmbH, Germany | Philipp Badorrek, Head of Department, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Germany | Dr Diana Sims-Silbermann, Senior Trial Manager, Early Development and Clinical Pharmacology, Janssen-Cilag GmbH, Johnson & Johnson, Germany | Hayley Jewell, Regional Director Clinical Operations, Eli Lilly, USA
|       | Isabelle Neije, Clinical Trial Head, GDO Trial Management Company, Novartis Pharma AG, Switzerland | Bettina Bergtholdt, Managing Partner, Emovis GmbH, Germany | Dr Joana Claverol Torres, Coordinator of the Clinical Trials Unit, Sant Joan de Deu Hospital, Spain | Geoff Taylor, Director, Clinical Quality Assurance, Eisai Product Creation Systems, UK
|       | Arjan Ooms, Clinical Research Manager, MSD, The Netherlands | Dr Michael Zörer, Head of Department, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Germany | Hans van Dijk, Chief Operating Officer, Julius Clinical, The Netherlands | Dr Michael Zörer, Head of Clinical Operations, AOP Orphan Pharmaceuticals AG, Austria
|       | Birgitte Segaard, Divisional Director, Clinical & Quantitative Pharmacology, H. Lundbeck A/S, Denmark | MODERATOR: Fraser Inglis, Consultant Physician & Director, Glasgow Memory Clinic, UK | | Van Zyl Engelbrecht, Director, Clinical Research, UBC, UK
|       | Bryan Katz, Managing Director of Consulting, INC Research/inVentiv Health, USA | Philipp Badorrek, Head of Department, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Germany | | Melissa Bomken, Vice President, Global Alliance Management, Strategic Resourcing, INC Research/inVentiv Health, USA
| 15:10 | Afternoon Break | | | |
| 16:00 | KEYNOTE PRESENTATION: Assessing the value of partnerships | PRESENTATION: Future of investigator and industry collaboration | CASE STUDY: Supercharging clinical trials - utilizing longitudinal linked patient level data to improve the commercial and academic research environment in the NHS | CASE STUDY: Vendor oversight, challenges and regulatory frameworks
|       | Dr Michael Mihut, Portfolio Management Officer, The Special Programme for Research and Training in Tropical Diseases, World Health Organization, Switzerland | Dr Mark Turner, Chair, European Network of Paediatric Research, European Medicines Agency and Liverpool University | Shizlene Oh, Senior Director, Imperial College Health Partners, UK | Christian Langelaueendeck, Global Clinical Operations Vendor Manager, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
|       | | Ian Riley, Director of Business Intelligence, North West London Collaboration of CCG’s, UK | |
17:10 Opening remarks from the Chairperson
Graham Belgrave, Independent Clinical Research Consultant

17:15 Lifetime Achievement Award presented by mdgroup

17:20 Inspirational Talk
For decades, Marc Koska OBE fought to stop the reuse of syringes. One of the most impressive and inspirational entrepreneurs in the world, Marc faced and broke down bureaucratic barriers to fight one of the most virulent contributors to the spread of AIDS, with his non-retractable syringe, which was endorsed by the World Health Organisation in 2015. Marc’s prolific work is truly inspirational and uplifting.

18:00 Join us in our very own Winter Wonderland
Drinks Reception at the RAI Boathouse (see page 7 for details)

MEDIA PARTNERS

[Logos of various media partners]
### STREAM 5
**PARTNERSHIP MANAGEMENT**

**Room:** Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55</td>
<td>Opening remarks from the Chairperson</td>
</tr>
<tr>
<td></td>
<td><strong>Lesley Mathews</strong>, Global Development</td>
</tr>
<tr>
<td></td>
<td>- Portfolio &amp; Operations, Resource Management &amp; System integration,</td>
</tr>
<tr>
<td></td>
<td><strong>Bayer Healthcare</strong></td>
</tr>
<tr>
<td>11:00</td>
<td>KEYNOTE: Future of healthcare: Integration of healthcare and research to</td>
</tr>
<tr>
<td></td>
<td>better understand disease and improve health</td>
</tr>
<tr>
<td></td>
<td><strong>Dr Greg Koski</strong>, Chairman, Co-Founder &amp; President / Chief Executive</td>
</tr>
<tr>
<td></td>
<td><strong>Executive Officer, ACRES Associate Professor of Anesthesia</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Massachusetts General Hospital, Harvard Medical School, USA</strong></td>
</tr>
<tr>
<td>11:30</td>
<td>CASE STUDY: Maximizing outcomes in asset transfers</td>
</tr>
<tr>
<td></td>
<td><strong>Ben Dudley</strong>, Vice President Strategic Account Leader,</td>
</tr>
<tr>
<td></td>
<td><strong>PAREXEL, UK</strong></td>
</tr>
</tbody>
</table>

### STREAM 6
**PATIENTS AS PARTNERS**

**Room:** E103

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55</td>
<td>Opening remarks from the Chairperson</td>
</tr>
<tr>
<td></td>
<td><strong>Jean Edwards</strong>, Consultant, Former Procurement Director, <strong>Eli Lilly</strong>, UK</td>
</tr>
<tr>
<td>11:00</td>
<td>KEYNOTE CASE STUDY: Implementation of patient engagement in drug development</td>
</tr>
<tr>
<td></td>
<td><strong>Adama Ibrahim</strong>, Senior Clinical Operations Lead, <strong>Biogen, UK</strong></td>
</tr>
<tr>
<td>11:30</td>
<td>PRESENTATION: Real patient voices for better trial design.</td>
</tr>
<tr>
<td></td>
<td><strong>#HumanBehindEveryNumber initiative</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Mike Jagielski</strong>, CEO, <strong>KCR, Poland</strong></td>
</tr>
</tbody>
</table>

### STREAM 7
**DISRUPTIVE INNOVATION, TECHNOLOGY AND BIG DATA**

**Room:** E104

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55</td>
<td>Opening remarks from the Chairperson</td>
</tr>
<tr>
<td></td>
<td><strong>Dr John Gate</strong>, European Procurement Executive, <strong>Eli Lilly &amp; Co Ltd, UK</strong></td>
</tr>
<tr>
<td>11:00</td>
<td>KEYNOTE: Opportunities to innovate in the way we collect data in clinical trials and how to manage volume, variety and veracity in a clinical study setting</td>
</tr>
<tr>
<td></td>
<td><strong>Matthew Bonam</strong>, Director, <strong>Intelligent Pharmaceuticals, AstraZeneca R&amp;D, UK</strong></td>
</tr>
<tr>
<td>11:30</td>
<td>PRESENTATION: Why hasn’t technology transformed clinical trial performance – Yet?</td>
</tr>
<tr>
<td></td>
<td><strong>Rik Van Mol</strong>, VP, <strong>Veeva Vault Europe, Veeva Systems, UK</strong></td>
</tr>
</tbody>
</table>

### STREAM 8
**SMALL TO MID-SIZE PHARMA AND BIOTECH**

**Room:** E105-106

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55</td>
<td>Opening remarks from the Chairperson</td>
</tr>
<tr>
<td></td>
<td><strong>Anna Matranga</strong>, Strategic Sourcing R&amp;D, Consultant, <strong>AMC Alliances &amp; Consulting, France</strong></td>
</tr>
<tr>
<td>11:00</td>
<td>CASE STUDY: Cooperation of Academia with SME for orphan drug developments</td>
</tr>
<tr>
<td></td>
<td><strong>Professor Ruth Ladenstein</strong>, Senior Consultant in Paediatric haematology–Oncology, <strong>ORiS, Austria</strong></td>
</tr>
<tr>
<td>11:30</td>
<td>CASE STUDY: Better trial management through clarity and collaboration</td>
</tr>
<tr>
<td></td>
<td><strong>Matt Denomney</strong>, Director, <strong>Trial Oversight Delivery, ERT</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Stream 5</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
</tr>
<tr>
<td>14:00</td>
<td>CASE STUDY: Engaging early to maximize value: The benefits of unifying technology and service partners early in protocol development</td>
</tr>
<tr>
<td></td>
<td>Adam Halbridge, Co-Founder of Parallel6, a PRA Health Sciences Company, USA</td>
</tr>
<tr>
<td>14:30</td>
<td>CASE STUDY: Implementation and ongoing oversight of a new global clinical program management Functional Service Provider (FSP) model from both a CRO and a sponsor perspective</td>
</tr>
<tr>
<td></td>
<td>Eleanor Clark, Senior Manager, Amgen, USA Jon Harris, Vice President DOCS Operations, ICON, Spain</td>
</tr>
<tr>
<td>15:00</td>
<td>PRESENTATION: Real RMB: A hype or common sense?</td>
</tr>
<tr>
<td></td>
<td>Igor Stefanov, CEO, Synergy, Purance; Artem Andrianov, CEO, Cyntegrity, Germany</td>
</tr>
<tr>
<td>15:30</td>
<td>PANEL: Exploring and challenging those common obstacles to meaningful patient involvement in clinical research.</td>
</tr>
<tr>
<td></td>
<td>MODERATOR: Claire Nolan, Research Involvement Manager, Parkinson’s UK Nathalie Bére, Patients Relations Coordinator, European Medicines Agency (EMA), UK Andy Gibson, Associate Professor in Patient and Public Involvement (PPI), University of Western England, UK Dr Julie Hapeshi, Associate Director R&amp;D, Gloucestershire Research Support Service, UK Marleen Kauter, Founding President, PSC Patients Europe, Netherlands David Spillert, Key Account Director, World Courier, UK</td>
</tr>
<tr>
<td>15:50</td>
<td>CASE STUDY: Paediatric specificities for clinical research</td>
</tr>
<tr>
<td></td>
<td>Dr Mark Turner, Chair, European Network of Paediatric Research, European Medicines Agency and Liverpool University</td>
</tr>
</tbody>
</table>

12:40 Lunch

16:10 End of Conference
## DAY ONE · TUESDAY 28TH NOVEMBER 2017

### EARLY CLINICAL DEVELOPMENT 2017

### CLINICAL TRIAL SUPPLY

#### PCT PLENARY Room: Forum

**07:30** Registration and Morning Coffee

**08:50** Opening remarks from the Chairperson

Anna Matranga, Strategic Sourcing R&D, Consultant, AMC Alliances & Consulting, France

**09:00** The world in reset mode: The new world competitiveness landscape and its impact on the pharmaceutical industry

Stephane Garelli, Professor of competitiveness (nations and enterprises), IMD Business School in Lausanne and University of Lausanne, Switzerland

#### SCIENCE IN EARLY PHASE Room: E108

**Chair: David Jones**, Expert Pharmacology-Toxicologist, Clinical trials Unit, MHRA

**11:00 DUAL DIALOGUE: Examining the impact of the FIH guideline update: Sponsor experience**

Sam Hariry, Head of Clinical Strategy, Novartis

Jeroen Bos, Global Therapeutic Area Lead - Drug Regulatory Affairs, Novartis

**11:30 PANEL DISCUSSION. An update on the FIH guideline: Where are we now?**

**Moderator: David Jones**, Expert Pharmacology-Toxicologist, Clinical trials Unit, MHRA

Kirsty Wydenbach, Deputy Unit Manager, MHRA

Dr Jan Willem van der Laan, Senior Pharmacological-Toxicological Assessor, Medicines Evaluation Board, The Netherlands

**12:05 FIH Cannabis Trial: Overview of the pharmacokinetic and pharmacodynamic results from single- and multi-ascending doses of dried cannabis delivered by smoking/inhalation**

Marc Lefebvre, Vice President Scientific and Regulatory Affairs, Altasciences

**12:35 Networking lunch** sponsored by Cytotherapy

#### OPERATIONAL STRATEGIES Room: E107

**Chair: Dr Stephen A Harrison**, GSK Associate Fellow, Clinical Program Lead, Clinical Pharmacology Study Science and Operations UK, GSK, UK

**11:00 PANEL DISCUSSION: Adapting to the new landscape for early clinical development: where are we now?**

**Moderator: Wolfgang Eglmeier**, Head Centre for Clinical Trials, Witten/Herdecke University

Dr Emma Dean, Director Physician, Early Clinical Development, Oncology Translational Medicine Unit, AstraZeneca, UK

Muna Kugler, Strategic Sourcing Manager, Global Operations, Idorsia Pharmaceuticals

Marc Hoffman, Chief Medical Officer, Celerion

**11:30 Dual Dialogue: Boehringer Ingelheim case study: Adaptive trial case study: Strategies for improving efficiency through technology and achieving more for less**

Thomas Bogentrieder, Boehringer Ingelheim

**12:05 What’s HAP-pening: A Current Primer in the Assessment of Human Abuse Potential**

Ryan Turncliff, Senior Director, Global Scientific Affairs, PRA

**12:35 Q&A Session: A chance for questions from the morning so far**

#### CLINICAL TRIAL SUPPLY Room: Hall 10

**Chair: Jackie Peck**, Director, Pharmacy Consulting Limited, UK

**11:40 Panel: The partnership landscape - New partnerships, new innovations, new processes**

**MODERATOR: Phil Hammond GP and Broadcaster**

Sheryl Jacobs, Vice President, Global Development Operations, Amgen Inc, USA

Barbara Voith, Vice President, Head Global CS Operations, Bayer HealthCare, Germany

Dr Emma Dean, Director Physician, Early Clinical Development, Oncology Translational Medicine Unit, AstraZeneca, UK

Hanne Lang, Vice President, Clinical Systems and Data Management, Novo Nordisk

Bryan Katz, Managing Director of Consulting, INC Research/inVentiv Health, USA

**11:40 Exploring latest status and timelines of the EU Clinical Trial Regulation (CTR) and implications for industry**

Cristiana Spontoni, Partner, JONES DAY*, Belgium

**11:40 Combined strengths: How partnership in transport and packaging leads to reduced temperature deviations and cost for IMP supplies**

Dr Roland Schuetze, Director Healthcare, Marketing International, TNT; The Netherlands

Christopher Storch, Global Head of Sales, va-Q-tec Group, Germany

Marcel Walraven, Product Manager Healthcare, TNT; The Netherlands

**12:05 Exploring latest progress and practicalities of direct-to-patient clinical trials**

Ramón López, Clinical Research Manager, Thrombotargets Europe, Spain

**12:05 INTERACTIVE ROUND TABLE DISCUSSION: Discussing the challenges of technology to monitor patient compliance**

Nina Cianfanelli Svennum, Clinical Supply Specialist, H. Lundbeck A/S, Denmark

---

**10:20 Morning Coffee and Networking** sponsored by PACE
16:00 How to mitigate risks and uncertainties identified in the preclinical setting in a first in human protocol
Ann Marie Janson Lang, Assoc. Prof. Expert, Medical Products Agency

16:00 Automating early phase clinical trials in an evolving technology landscape
Duncan Kemp, Executive Director of UK Operations, Development, OmniComm Systems, Inc.

16:00 Exploring the practicalities of Investigator initiated trials (IIT) and clinical trial supply chain considerations
Samantha Carmichael, Lead Pharmacist Clinical Trials / R&D, NHS Greater Glasgow & Clyde, UK

16:30 An update on the clinical trial regulation: Regulatory authority feedback
Lene Grejs Petersen, Senior Adviser, Clinical Trials, Danish Medicines Agency

16:30 PANEL DISCUSSION: Examining outsourcing models in early clinical development: What are the challenges and opportunities?
MODERATOR: Dr. John Gate, European Procurement Executive, Eli Lilly & Co Ltd, UK
Birgitte Søgaard, Divisional Director, Clinical & Quantitative Pharmacology, Lundbeck
Wolfgang Eglmeier, Head Centre for Clinical Studies Witten/Herdecke University
Kieran Canisius, Managing Partner, Suess Consult, The Netherlands

16:30 Clinical pharmacy perspective: Cooperation with industry at early stages of clinical trial supply and working successfully with partners
Marija Tubic Grozdanis, Lead Pharmacist Clinical Trials, University Medical Center of the Johannes Gutenberg University Mainz, Germany

17:10 Opening remarks from the Chairperson
Graham Belgrave, Independent Clinical Research Consultant

17:15 Lifetime Achievement Award presented by rm group

17:20 Inspirational Talk
For decades, Marc Koska OBE fought to stop the reuse of syringes. One of the most impressive and inspirational entrepreneurs in the world, Marc faced and broke down bureaucratic barriers to fight one of the most virulent contributors to the spread of AIDS, with his non-retractable syringe, which was endorsed by the World Health Organisation in 2015. Marc’s prolific work is truly inspirational and uplifting.

18:00 Join us in our very own Winter Wonderland Drinks Reception at the RAI Boathouse (see page 7 for details)
### REGULATORY AND SCIENCE
Room: E108

**Chair:** David Jones, Expert Pharmacotoxicologist, Clinical trials Unit, MHRA

11:00 **Modelling and biomarkers: The Role of Human Models of Disease State to Accelerate Early Clinical development in Healthy Volunteers and Patients**
Dr John Connell, Chief Research & Development Officer, MAC Clinical Research

11:30 **Cell-based biomarkers as a means of confirming target engagement and mechanism in early clinical trials**
Neil Williams, CSO, KWS BioTest

### OPERATIONAL STRATEGIES
Room: E107

**Chair:** Dr Stephen A Harrison, GSK Associate Fellow, Clinical Program Lead, Clinical Pharmacology Study Science and Operations UK, GSK

11:00 **Patient Centricity and Patient Recruitment: Getting the balance right in the design of early phase patient studies**
Stephen A Harrison, PhD, GSK Associate Fellow, Clinical Program Lead, Clinical Pharmacology Study Science and Operations UK, GSK

11:30 **Building unique partnerships to facilitate the transition from healthy volunteer to patient studies**
Jim Bush, MChB, PhD, MRCs, MFPM, Medical Director, Covance Clinical Pharmacology Services
Dr Richard FitzGerald, Consultant Physician and Director, Clinical Research Unit. Royal Liverpool University Hospital

12:00 **Recruiting patients in early clinical development through effective collaborations**
Muna Kugler, Strategic Sourcing Manager, Global Operations, Morsia Pharmaceuticals

### CLINICAL TRIAL SUPPLY
Room: Hall 10

**Chair:** Frank Peeters, Managing Director, Toebas bvba, Belgium

11:00 **GI perspective: Exploring how global standards can be used to address efficiency, accuracy and surety in the clinical trial supply chain**
Tania Snijich, Director Healthcare, GSI Global Office, Belgium

11:30 **Highlighting the importance of quality sample management in the development of immunotherapies**
Jennifer Brandl, Associate Manager, Clinical Trials, Immune Design, USA

12:00 **INTERACTIVE ROUND TABLES: Sharing experiences with using latest strategies and tools for clinical supply chain forecasting and planning**
Anuja Shukla, Clinical Supply Lead, UCB Pharma S.A., Belgium

### SYMPOSIUM AGENDAS - 28TH & 29TH NOVEMBER 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Modelling and biomarkers: The Role of Human Models of Disease State to Accelerate Early Clinical development in Healthy Volunteers and Patients&lt;br&gt;Dr John Connell, Chief Research &amp; Development Officer, MAC Clinical Research</td>
</tr>
<tr>
<td>11:30</td>
<td>Cell-based biomarkers as a means of confirming target engagement and mechanism in early clinical trials&lt;br&gt;Neil Williams, CSO, KWS BioTest</td>
</tr>
<tr>
<td>12:00</td>
<td>Building unique partnerships to facilitate the transition from healthy volunteer to patient studies&lt;br&gt;Jim Bush, MChB, PhD, MRCs, MFPM, Medical Director, Covance Clinical Pharmacology Services&lt;br&gt;Dr Richard FitzGerald, Consultant Physician and Director, Clinical Research Unit. Royal Liverpool University Hospital</td>
</tr>
<tr>
<td>12:30</td>
<td>Networking lunch</td>
</tr>
<tr>
<td>13:00</td>
<td>Translational Modeling in support to safety and efficacy assessment during early development&lt;br&gt;Thierry Lave, Principal Leader, Head Project Leader and M&amp;S, Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche</td>
</tr>
<tr>
<td>13:30</td>
<td>ICH guideline E14: Regulatory perspective on cardiac safety assessment&lt;br&gt;Colette Strnadova, Senior Scientific Advisor / Health Products and Food Branch, Health Canada</td>
</tr>
<tr>
<td>14:00</td>
<td>Recruiting patients in early clinical development through effective collaborations&lt;br&gt;Muna Kugler, Strategic Sourcing Manager, Global Operations, Morsia Pharmaceuticals</td>
</tr>
<tr>
<td>14:30</td>
<td>examinig the trend towards adaptive trial design: Where are we now?&lt;br&gt;Dr Stuart Oliver, Medical Director, Early Clinical Development, Quintiles, UK</td>
</tr>
<tr>
<td>15:00</td>
<td>Cardiac safety and the use of early trials data instead of the TQT trial&lt;br&gt;Corina Dota, Director, AZ Cardiovascular Safety Centre of Excellence, AstraZeneca</td>
</tr>
<tr>
<td>15:30</td>
<td>TRI-DIALOGUE: QT Prolongation: Implementation guidance for industry&lt;br&gt;Corina Dota, Director, AZ Cardiovascular Safety Centre of Excellence, AstraZeneca&lt;br&gt;Colette Strnadova, Senior Scientific Advisor / Health Products and Food Branch, Health Canada&lt;br&gt;Dr Borje Darpo, CSO, Associate Professor of Cardiology, Cardiac Technologies</td>
</tr>
<tr>
<td>16:00</td>
<td>End of conference</td>
</tr>
</tbody>
</table>